Dermorphin | Buy Research-Grade Dermorphin in Europe | ≥99% Purity

Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American frogs of the Phyllomedusa genus, available to buy in Europe for laboratory research into opioid receptor pharmacology, mu-opioid receptor biology, pain signalling mechanisms, and the structure-activity relationships of peptide opioid ligands.

Laboratories and research institutions across the EU can order verified, research-grade Dermorphin with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA)

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to EU & Europe | Tracked Shipping

What is Dermorphin?

Dermorphin is a naturally occurring heptapeptide — sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 — first isolated in 1981 by Vittorio Erspamer and colleagues from the skin secretions of the South American tree frog Phyllomedusa sauvagei. Its discovery was immediately significant for two reasons: it was the first naturally occurring peptide found to contain a D-amino acid (D-alanine at position 2) in an animal — rather than bacterial — source, and it demonstrated opioid receptor binding affinity and selectivity vastly exceeding that of morphine — establishing dermorphin as one of the most potent naturally occurring mu-opioid receptor (MOR) agonist peptides ever characterised.

The presence of D-alanine at position 2 — an unusual feature for an animal peptide, as most biological peptides are composed exclusively of L-amino acids — is essential for dermorphin’s exceptional mu-opioid receptor affinity and its resistance to enzymatic degradation compared to L-amino acid peptides. This D-amino acid incorporation is now understood to reflect a post-translational isomerisation process in Phyllomedusa skin glands — an extraordinary biological mechanism that produces a peptide with pharmacological properties qualitatively different from anything achievable with standard L-amino acid composition alone.

Dermorphin’s exceptional MOR selectivity — binding mu-opioid receptors with approximately 1000-fold greater affinity than morphine and with high selectivity over delta and kappa opioid receptor subtypes — has made it one of the most important reference ligands in opioid receptor pharmacology research. Its well-characterised receptor binding profile, peptide structure amenable to systematic modification, and natural origin as a skin defence peptide have established dermorphin as a foundational tool in opioid receptor biology, peptide analgesic research, and the medicinal chemistry of opioid peptide ligands — making it a compound of enduring research interest in European pharmacology and neuroscience laboratories.

What Does Dermorphin Do in Research?

In laboratory settings, dermorphin is studied primarily as a highly selective mu-opioid receptor agonist and reference pharmacological tool, with research applications centred on opioid receptor biology, pain signalling, and peptide opioid medicinal chemistry. EU and European researchers working with dermorphin typically focus on:

• Mu-opioid receptor pharmacology — dermorphin is one of the most selective and potent naturally occurring mu-opioid receptor agonists characterised — making it the reference peptide ligand for MOR binding assays, receptor activation studies, downstream signalling characterisation, and comparative opioid receptor pharmacology research. Its exceptional MOR affinity and selectivity over delta and kappa subtypes make it a preferred tool for studies requiring clean MOR engagement.
• Opioid receptor binding and selectivity research — studies use dermorphin in competitive radioligand binding assays to characterise opioid receptor subtype selectivity, examine receptor binding kinetics, and benchmark the MOR affinity of novel opioid compounds — establishing it as a standard reference ligand in opioid receptor binding research.
• Pain signalling and antinociception research — dermorphin’s MOR agonism produces potent antinociceptive effects in pre-clinical pain models — including hot plate, tail flick, and writhing assays — making it a reference compound for studying mu-opioid receptor-mediated pain modulation and the central and peripheral mechanisms of opioid antinociception.
• Opioid receptor signalling pathway research — MOR activation by dermorphin drives Gi/o protein-coupled signalling — inhibiting adenylyl cyclase, activating GIRK channels, and modulating calcium channel activity in neurons. Studies use dermorphin to examine the intracellular signalling cascades downstream of MOR activation and how receptor coupling efficiency and signalling bias influence opioid pharmacological effects.
• Peptide opioid structure-activity relationship research — dermorphin’s heptapeptide structure — particularly its D-alanine at position 2 — provides a well-defined starting scaffold for systematic structure-activity relationship studies examining how amino acid substitutions, D-amino acid positions, C-terminal modifications, and cyclisation influence MOR binding affinity, selectivity, and functional activity. This SAR research has made dermorphin a foundational scaffold in peptide opioid medicinal chemistry.
• D-amino acid biology in peptide pharmacology — dermorphin’s D-alanine at position 2 is essential for its exceptional MOR affinity and enzymatic stability — making it a model compound for studying how D-amino acid incorporation influences peptide receptor pharmacology, metabolic stability, and bioavailability in the broader context of D-amino acid peptide medicinal chemistry.
• Opioid tolerance and dependence research — studies have examined dermorphin in pre-clinical tolerance and dependence models — characterising how repeated MOR activation by this highly potent agonist influences receptor internalisation, desensitisation, and the cellular adaptations underlying opioid tolerance — contributing to understanding of the neurobiological mechanisms of opioid tolerance development.
• Beta-arrestin and biased agonism research — MOR agonists differ in their relative activation of G-protein versus beta-arrestin signalling pathways — a phenomenon termed biased agonism that has significant implications for opioid pharmacology research. Dermorphin is used as a reference MOR agonist in biased agonism studies examining how different opioid ligands differentially engage these downstream pathways and how signalling bias influences the pharmacological profile of MOR activation.
• Opioid receptor internalisation research — studies have characterised dermorphin-induced MOR internalisation — examining how agonist-driven receptor endocytosis influences opioid receptor recycling, resensitisation, and the dynamic regulation of MOR surface expression in neurons — contributing to understanding of the cellular mechanisms regulating opioid receptor availability.
• Endogenous opioid system research — dermorphin is used as a reference exogenous MOR agonist in studies examining how the endogenous opioid system — including enkephalins, endorphins, and endomorphins — modulates pain, reward, stress, and autonomic function through mu-opioid receptor engagement. Its high selectivity makes it a clean pharmacological tool for dissecting MOR-specific contributions to endogenous opioid system biology.
• Spinal and supraspinal opioid pharmacology — dermorphin’s well-characterised antinociceptive profile has been studied at both spinal and supraspinal levels — with studies examining MOR agonism in the periaqueductal grey, rostral ventromedial medulla, and spinal dorsal horn to characterise the neural circuits mediating opioid antinociception and the site-specific contributions of MOR activation to pain modulation.
• Comparative frog skin peptide pharmacology — dermorphin is studied alongside other Phyllomedusa skin peptides — including deltorphins, phyllocaerulein, and sauvagine — as part of the broader research programme examining how amphibian skin gland peptides have evolved to target mammalian receptor systems with exceptional potency and selectivity. This comparative pharmacology research has contributed to fundamental understanding of opioid receptor evolution and ligand design principles.

All research applications are for in vitro and pre-clinical use only.

What Do Studies Say About Dermorphin?

Dermorphin has an extensive and well-characterised research literature spanning over four decades — with studies establishing its foundational importance in opioid receptor pharmacology, peptide opioid medicinal chemistry, and pain signalling research.

Discovery and receptor characterisation: Erspamer’s 1981 discovery of dermorphin was immediately followed by studies characterising its extraordinary mu-opioid receptor affinity — with binding assays documenting MOR affinity approximately 1000-fold greater than morphine and high selectivity over delta and kappa opioid receptors. These foundational pharmacological characterisations established dermorphin as the reference high-affinity MOR peptide agonist and triggered decades of subsequent research into its structure-activity relationships and pharmacological applications.

D-amino acid significance: Studies examining the importance of D-alanine at position 2 for dermorphin’s pharmacological profile have documented that replacement with L-alanine dramatically reduces MOR affinity and antinociceptive potency — establishing the D-amino acid as essential for the receptor binding geometry producing dermorphin’s exceptional MOR engagement. This finding has had broad implications for peptide medicinal chemistry — establishing D-amino acid incorporation as a validated strategy for optimising opioid peptide receptor affinity and metabolic stability.

Antinociception research: Pre-clinical studies have consistently documented dermorphin’s potent antinociceptive effects across multiple pain model systems — including hot plate, tail flick, formalin, and writhing assays — with findings establishing its antinociceptive potency significantly exceeding that of morphine on a molar basis. Studies examining spinal versus supraspinal administration have characterised the site-specific contributions of MOR activation to dermorphin’s overall antinociceptive profile.

Structure-activity relationship research: Dermorphin has served as one of the primary scaffolds for systematic peptide opioid SAR research — with studies examining hundreds of analogues incorporating amino acid substitutions, truncations, cyclisations, and D-amino acid variations to characterise the structural requirements for MOR affinity, selectivity, and functional activity. This SAR literature has contributed foundational knowledge to opioid peptide medicinal chemistry and has informed the design of novel opioid research tools.

Receptor internalisation and tolerance studies: Studies examining dermorphin-induced MOR internalisation and tolerance have characterised the cellular dynamics of MOR trafficking — documenting agonist-driven receptor internalisation, intracellular trafficking, and recycling patterns that influence opioid receptor resensitisation and the development of tolerance to repeated opioid exposure.

Signalling pathway characterisation: Research has characterised dermorphin’s downstream MOR signalling — documenting Gi/o coupling, adenylyl cyclase inhibition, GIRK channel activation, and calcium channel modulation in MOR-expressing cell systems. These signalling characterisations have contributed to the broader literature on MOR signal transduction and how agonist pharmacological properties influence the balance of G-protein versus arrestin pathway engagement.

Comparative amphibian peptide research: Studies examining dermorphin alongside other Phyllomedusa skin peptides have contributed to understanding of how this frog genus has evolved a remarkably diverse pharmacopoeia of bioactive peptides targeting mammalian receptor systems — including opioid receptors (dermorphin, deltorphins), neurotensin receptors (phyllocaerulein), and CRH receptors (sauvagine) — providing insights into the evolutionary convergence of amphibian defensive chemistry and mammalian neuropeptide receptor biology.

Dermorphin vs Related Opioid Receptor Research Compounds

Compound	Type	Receptor Selectivity	Key Research Application
Dermorphin	Natural heptapeptide — D-Ala2	MOR highly selective — very high affinity	Reference MOR peptide agonist, SAR scaffold, antinociception research
DAMGO	Synthetic enkephalin analogue	MOR selective	Standard MOR reference agonist — binding assays, signalling research
Morphine	Alkaloid opioid	MOR preferring — some KOR	Reference non-peptide MOR agonist, tolerance/dependence models
Deltorphin I/II	Phyllomedusa skin peptides	DOR highly selective	Reference delta-opioid receptor peptide agonists — comparative opioid research
DPDPE	Synthetic enkephalin analogue	DOR selective	Delta-opioid receptor pharmacology reference
Endomorphin-1/2	Endogenous tetrapeptides	MOR selective	Endogenous MOR ligand biology, comparative peptide opioid research

Buying Dermorphin in Europe — What’s Included

Every order of Dermorphin peptide dispatched to EU and European research institutions includes:

• Batch-Specific Certificate of Analysis (CoA)
• HPLC Chromatogram
• Mass Spectrometry Confirmation
• Sterility and Endotoxin Testing Reports
• Reconstitution Protocol
• Technical Research Support

Frequently Asked Questions — Dermorphin Peptide EU

Can I Buy Dermorphin in the EU and Europe?

Yes. We supply research-grade Dermorphin with fast tracked international dispatch to all EU member states and wider European destinations including Germany, France, Netherlands, Spain, Italy, Poland, and beyond. Packaging is designed to maintain peptide integrity throughout transit and all orders include full batch documentation. Dermorphin is supplied strictly for laboratory research use only and must be handled in compliance with applicable national regulations governing opioid research compounds.

What Makes Dermorphin’s MOR Affinity so Exceptionally High Compared to Morphine?

Dermorphin’s exceptional mu-opioid receptor affinity — approximately 1000-fold greater than morphine — results from the combination of its D-alanine at position 2 and the overall heptapeptide sequence geometry that produces near-optimal engagement with the MOR binding pocket. The D-alanine substitution constrains the peptide backbone conformation at position 2 to a geometry that places the downstream pharmacophore elements — particularly the Phe3 aromatic ring and the Tyr1 hydroxyl group — in the precise spatial arrangement required for high-affinity MOR engagement. Additionally, D-amino acid incorporation protects the peptide from dipeptidyl peptidase cleavage at the N-terminal Tyr-D-Ala bond — extending its biological activity window in research systems. The combination of optimal receptor binding geometry and improved enzymatic stability distinguishes dermorphin’s pharmacological profile from both morphine and L-amino acid opioid peptides.

What is the Significance of D-Amino Acids in Dermorphin’s Structure?

The D-alanine at position 2 of dermorphin is one of the most pharmacologically significant D-amino acid residues identified in any naturally occurring animal peptide — and its discovery in dermorphin in 1981 fundamentally influenced peptide medicinal chemistry. Prior to dermorphin’s discovery, D-amino acids in animal peptides were essentially unknown — their presence was considered a bacterial or fungal characteristic. Dermorphin demonstrated that animal biosynthetic machinery could produce D-amino acid-containing peptides through post-translational isomerisation, and that D-amino acid incorporation could dramatically enhance peptide receptor pharmacology. This discovery triggered systematic investigation of D-amino acid incorporation as a medicinal chemistry strategy — influencing the design of research peptides and drug candidates across multiple receptor classes beyond opioids.

What is the Difference Between Dermorphin and Deltorphin in Opioid Research?

Dermorphin and the deltorphins are both naturally occurring D-amino acid-containing opioid peptides from Phyllomedusa frog skin — but with complementary receptor selectivity profiles that make them equally important but distinct research tools. Dermorphin is highly selective for mu-opioid receptors — making it the reference tool for MOR pharmacology research. Deltorphins (deltorphin I: Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 and deltorphin II: Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2) are highly selective for delta-opioid receptors — making them the reference tools for DOR pharmacology research. The two peptide families are studied as complementary tools enabling pharmacological dissection of MOR versus DOR contributions to opioid system biology.

What is the Difference Between Dermorphin and DAMGO in MOR Research?

Both dermorphin and DAMGO (D-Ala2-MePhe4-Gly-ol5 enkephalin) are widely used as reference MOR agonist research tools, but they differ in origin, structure, and specific research applications. DAMGO is a synthetic enkephalin analogue designed specifically as a selective MOR research tool — widely used in radioligand binding assays and signalling studies as the standard MOR reference agonist. Dermorphin is a naturally occurring heptapeptide with a distinct structural scaffold — providing a different molecular geometry for receptor engagement and serving as both a pharmacological tool and a medicinal chemistry scaffold for SAR research. The two compounds are complementary reference ligands used in parallel in MOR pharmacology research to confirm receptor selectivity and compare agonist properties.

How Do I Reconstitute Dermorphin for Laboratory Use?

Allow the vial to reach room temperature before opening. Add sterile water or an appropriate laboratory buffer slowly down the vial wall and swirl gently — do not shake. Dermorphin is soluble in aqueous buffers — prepare at your protocol’s required concentration, aliquot, and store at -80°C to minimise freeze-thaw degradation. The D-alanine at position 2 confers improved enzymatic stability compared to all-L-amino acid opioid peptides — but standard peptide handling protocols should be followed to maintain biological activity. Prepare working solutions fresh where possible and handle on ice during experimental procedures.

How Quickly is Dermorphin Delivered to Europe?

Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to protect peptide stability throughout transit.

Product Specifications

Parameter	Detail
Sequence	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2
Type	Naturally Occurring Heptapeptide Opioid — D-Amino Acid Containing
Source Origin	Phyllomedusa sauvagei frog skin secretion
Primary Receptor	Mu-Opioid Receptor (MOR) — highly selective, very high affinity
Key Structural Feature	D-Alanine at position 2 — essential for MOR affinity and enzymatic stability
Primary Research Interest	MOR pharmacology, opioid receptor biology, antinociception, peptide opioid SAR
Purity	≥99%
Verification	HPLC & Mass Spectrometry
Form	Sterile Lyophilised Powder
Solubility	Sterile water or laboratory buffer
Storage	-20°C, protected from light and moisture
Intended Use	Research use only

Research Disclaimer

Dermorphin is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. Dermorphin is an opioid receptor agonist research compound and must be handled solely by qualified researchers in full compliance with applicable EU regulations, national legislation governing opioid research compounds, institutional ethics guidelines, and all relevant controlled substance regulations in the researcher’s jurisdiction. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes within a licensed facility authorised to handle opioid research compounds.